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Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a rare,
progressive, neurodegenerative disease characterized by ataxia, spasticity and
polyneuropathy. First described in the French-Canadian population of Quebec in 1978,
ARSACS has since been identified in multiple patients worldwide. In this clinical case
report, we describe the evaluation of an 11-years-old African-American male who
presented to neuromuscular clinic for assessment of a gait abnormality. He had a history
of gross motor delay since early childhood, frequent falls and a below average IQ.
Chromosomal microarray revealed a 1.422 megabase loss in the 13q12.12 region, which
includes the SACS gene. Next Generation Sequencing then showed a novel, predicted
to be pathogenic missense mutation (c.11824dup) of this gene. His clinical presentation
and neurological imaging further confirmed the diagnosis of ARSACS. To our knowledge,
this is the first reported case of this disease in the African-American population of the
United States. This case report further highlights the growing trend of identifying genetic
diseases previously restricted to single, ethnically isolated regions in many different ethnic
groups worldwide.
Keywords: ARSACS, ataxia, Charlevoix-Saguenay, cerebellum, neurogenetics, polyneuropathy, spasticity, retina

BACKGROUND
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is a rare neurodegenerative
condition initially identified in the French-Canadian population in 1978 (1). Secondary to a
mutation of the SACS gene on chromosome 13q, this disease is characterized by cerebellar ataxia,
spasticity, polyneuropathy, nystagmus and retinal changes (2). It is inherited in an autosomal
recessive manner and typically manifests in early childhood as difficulty with ambulation and gait
unsteadiness. ARSACS is slowly progressive, eventually leading to loss of ambulation around age
40 (range 17–58) and death around age 50 (range 21–72) (3).
Originally characterized in two regions of northeastern Quebec previously settled by individuals
of French descent (4), ARSACS has since been identified in multiple patients worldwide. Whereas,
most of the affected patients in French-Canada had the same single nucleotide deletion in the exon
of the SACS gene, new missense mutations have been identified in individuals from Tunisia, Turkey,
Italy, Japan and multiple countries in Europe (5–11).
The worldwide incidence of ARSACS is unknown, though it is thought to be underdiagnosed.
Within the Saguenay-Lac-St-Jean region of Quebec, however, the estimated incidence is between
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FIGURE 1 | (A) Midsagittal MRI at age 3 showing no cerebellar changes at that time. (B) Midsagittal MRI at age 11 showing evidence of asymmetric volume loss
within the superior and middle components of the cerebellar vermis with preserved volume of the inferior component (red outline). (C) Axial plane MRI exhibiting faint
linear/T2 signal hypointensities within the Pons (red arrow).

distinct optic disc margins on fundoscopy (Figure 2A), and
symmetric pupils with no afferent defect. Subtle choreiform
movements were noted in the fingers with outstretched hands
and end point tremor on finger to nose testing was present. In
the lower extremities, there was increased tone of spastic nature.
Patellar reflexes were brisk and ankle jerks were decreased with
associated weakness. Cross adduction was present. His gait was
wide based and staggering; he was unable to perform tandem gait
testing. Spasticity with mild scissoring was apparent with casual
gait testing.
Brain MRI revealed asymmetric volume loss within the
superior and middle aspects of the cerebellar vermis relative
to the inferior aspect (Figure 1B) and faint linear T2 signal
hypointensities within the pons (Figure 1C), findings that
have been shown to be associated with ARSACS (14, 15).
Fundoscopic photography and Optical Coherence Tomography
both demonstrated hypertrophy of the retinal nerve fiber layer
and other retinal layers (Figures 2B,C), findings also observed in
ARSACS (16). Electromyography performed was abnormal for
both sensory and motor components in multiple nerves tested,
providing electrophysiological evidence for a sensory greater
than motor axonal polyneuropathy.
Initial chromosome microarray then showed a 1.422
megabase loss in the 13q12.12 region (Figure 3), of which
there are 14 genes present. Three of these genes have
autosomal recessive genetic conditions associated with
them, including Limb-girdle muscular dystrophy type 2C
(SGCG gene), ARSACS (SACS gene), and Combined oxidative
phosphorylation deficiency 31 (MIPEP gene). Subsequent
Next Generation Sequencing of these genes revealed that
the patient had hemizygous, likely pathogenic variant in the
SACS gene (c.11824dup), which was predicted to result in
a frameshift mutation with premature protein termination
(p.Met3942Asnfs∗ 4). Taken together, these clinical and genetic
findings are consistent with the diagnosis of ARSACS.
Current treatment is focused on symptomatic management
and improvement of daily life. Gait stabilization with the
wearing of ankle foot orthoses has been observed and
he has been receiving scheduled botox injections to the
bilateral hamstrings every 90 days with improvement in
flexibility.

1 in 1,500 to 2,000 individuals. The estimated carrier frequency
of SACS pathogenic variants is 1 in 21 individuals based on
population data accumulated between 1941 and 1985 (4, 12, 13).
In this clinical case report, we detail the first published case
of ARSACS in an African-American patient in the United States,
highlighting the clinical presentation, neurological imaging and
genetic analysis involved in diagnosis. Furthermore, we identified
a novel, predicted to be pathogenic missense mutation in the
SACS gene (c.11824dup) resulting in the ARSACS phenotype.

CASE PRESENTATION
An 11 years-old African-American male presented to pediatric
neuromuscular clinic for evaluation of gait abnormality. He had
a history of gross motor delay since age 3 and was enrolled in both
physical and occupational therapy. His mother noted frequent
falls, particularly when running or getting onto the school
bus, as well as chronic headaches and blurry vision. Previously
performed neuropsychological testing showed a below average
IQ and an MRI of the brain at age 3 was normal (Figure 1A).
An MRI of the lumbosacral spine from age 5 was also reportedly
normal. Prior laboratory evaluation, including CPK, ANA and
Acetylcholine receptor antibodies, was normal. He had never
had a formal eye exam. Family history was significant for a
maternal great grandfather who required leg braces starting at
age 6 (with removal around age 10), who also reportedly had a
similar posture as the patient. There was also a family history
of non-specific visual symptoms in multiple family members on
his mother’s side as well as an older sibling who previously had
seizures. He was not of French-Canadian descent, was the child
of a non-consanguineous conception and had two half-brothers
and one half-sister, all of whom were alive and well aside from
the aforementioned seizures. Both of his parents and all of his
grandparents were African-American as well.
On examination, he had gaze-evoked nystagmus and saccadic
dysmetria with undershoot saccades in all directions, prominent
white striations emanating adjacent to the optic nerve with
Abbreviations: ARSACS, Autosomal Recessive Spastic Ataxia of CharlevoixSaguenay.
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FIGURE 2 | (A) Fundus photography of the right and left eyes demonstrating peripapillary retinal nerve fiber hypertrophy and white striations emanating adjacent to
the optic nerve. (B) Posterior pole Optical Coherence Tomography demonstrating hypertrophy of the retinal nerve fiber layer and other inner retinal layers. (C) Selected
cross sections of the right and left eye demonstrating hypertrophy of the retinal nerve fiber layer and other inner retinal layers. Colors correspond to the retinal layers
depicted above.

DISCUSSION

A number of different mutations have been shown to cause the
ARSACS phenotype (18–20), which is thought to result from loss
of function of the encoded protein Sacsin. The exact role of this
large, 520-kDa cytoplasmic protein remains unknown, though
it has been proposed to have roles in mitochondrial function
(21), protein chaperoning (22), and the ubiquitin-proteasome
system (23). Further studies have shown that Sacsin knockout
results in increased reactive oxygen species production (24) and
alterations in synaptic input and intrinsic firing in cerebellar
Purkinje cells (25).
The observed genetics in this patient are atypical in that he is
a compound heterozygote, wherein full chromosomal deletion of

With the implementation of targeted high throughput
sequencing and identification of novel genetic mutations,
ARSACS, a disease previously reported primarily in the
French-Canadian population of Quebec, is now being
identified worldwide (17). Here, we have described the
clinical presentation, diagnostic evaluation and management of
the first reported case of ARSACS in the African-American
population. Furthermore, we identified a previously
unreported mutation in the SACS gene, designated c.
11824dup.
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FIGURE 3 | Chromosomal microarray showing 1.422 megabase loss in the 13q12.12 region containing 14 different genes, including the SACS gene.

worldwide prevalence will undoubtedly continue to rise as
further novel mutations are characterized.

one of the SACS genes combined with the observed frameshift
mutation (hemizygous) resulted in the ARSACS phenotype. A
hemizygous presentation of this disease has previously been
described in the Belgian population (26). These two cases are
unique in that they involve gross chromosomal deletion of the
SACS gene, whereas all previously reported mutations in patients
with ARSACS involved either point mutations or missense
mutations in this gene. Moderate perceptive hearing loss was
described as the only feature by which the Belgian patient with
ARSACS differed from other cases of the disease, however this
feature was not present in our patient.
Despite a family history of gait abnormalities on his mother’s
side, we cannot comment specifically on the nature of this
patient’s inheritance without formal genetic testing of his parents,
which has not been performed at this time. De novo or inherited
deletion of the SACS gene from one parent combined with
another de novo or inherited likely pathogenic variant from the
other parent would be a theory of inheritance compatible with
the history and known genetics of this patient.
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